1Tuttle RM,Lopez N,Leboeuf R,et al.Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function[J].Thyroid,2010,20(3):257-263.
2Lee N,Tuttle M.The role of external beam radiotherapy in the treatment of papillary thyroid cancer[J].Endocr Relat Cancer,2006,13(4):971-977.
3Brierley JD,Tsang RW.External beam radiation therapy for thyroid cancer[J].Endocrinol Metab Clin North Am,2008,37(2):497-509.
4Tuttle RM.NCCN Clinical Practice Guidelines in Oncology(NCCN GuidelinesTM)[J].Thyroid Cancer,Version2.2012.
5Hay ID.Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma[J].J Surg Oncol,2006,94(8):692-700.
6Sawka AM,Brierley JD,Tsang RW,et al.An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer[J].Endocrinol Metab Clin North Am,2008,37(2):457-480.
7Tuttle RM,Brokhin M,Omry G,et al.Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal[J].J Nucl Med,2008,49(5):764-770.
8Brown AP,Chen J,Hitchcock YJ,et al.The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer[J].J Clin Endocrinol Metab,2008,93(2):504-515.
9Sawka AM,Thabane L,Parlea L,et al.Second primary malignancy risk after radioactive iodine treatment for thyroid cancer:a systematic review and meta-analysis[J].Thyroid,2009,19(5):451-457.
10Grewal RK,Larson SM,Pentlow CE,et al.Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation[J].J Nucl Med,2009,50(10):1605-1610.
同被引文献29
1Kobayashi D, Kodera Y, Fujiwara M,et al. Assessment of quality of life after gastreetomy using EORTC QLQ-C30 and STO22[J]. World J Sury, 2011,35 (2) : 357-364.
